

IN THE CLAIMS

Please cancel claims 2 and 9 without prejudice. Please amend claims 1 and 3 as follows:

1. (Amended) [An isolated] A human [anti-CD40] monoclonal antibody or fragment thereof that specifically binds to human CD40 [and modulates an activity of CD40].
2. (Canceled) ~~The human anti-CD40 antibody of claim 1, wherein the antibody is monoclonal.~~
3. (Amended) The human [anti-CD40] antibody of claim [2] 1, wherein the antibody is produced by a hybridoma cell line or subclones thereof, and wherein the antibody is denoted as no. 11 or 72, or the hybridoma is denoted as F1-102, F5-152, F2-103, F5-77, F5-157 or F4-465.
4. (Amended) The human [anti-CD40] antibody of claim 1, wherein the antibody has the CD40 binding specificity of the antibody denoted as no. 11 or 72, or the antibody produced by the hybridoma denoted as F1-102, F5-152, F2-103, F5-77, F5-157 or F4-465.
5. (Amended) The human [anti-CD40] antibody of claim 1, wherein the antibody has a CD40 modulating activity of the antibody denoted as no. 11 or 72, or the antibody produced by the hybridoma denoted as F1-102, F5-152, F2-103, F5-77, F5-157 or F4-465.
6. (Amended) The human [anti-CD40] antibody fragment of claim 1, wherein the fragment comprises an scFv, Fab, Fab', or F(ab')₂ fragment.
7. (Amended) The human anti-CD40 antibody fragment of claim 6, wherein the fragment comprises a fragment of the antibody denoted as no. 11 or 72, or the antibody produced by the hybridoma denoted as F1-102, F5-152, F2-103, F5-77, F5-157 or F4-465.
8. (Amended) The human [anti-CD40] antibody of claim 1, wherein the antibody is detectably labeled.
9. (Canceled) ~~The human anti-CD40 antibody of claim 1, wherein the CD40 is human.~~
10. (Amended) The human [anti-CD40] antibody of claim 1, wherein the antibody decreases binding of a CD40 ligand to CD40.
11. (Amended) The human [anti-CD40] antibody of claim 1, wherein the antibody increases binding of a CD40 ligand to CD40.

12. (Amended) The human [anti-CD40] antibody of claim 1, wherein the antibody decreases a CD40 activity.
13. (Amended) The human [anti-CD40] antibody of claim 12, wherein the antibody contains a lambda light chain sequence.
14. (Amended) The human [anti-CD40] antibody of claim 12, wherein the antibody decreases proliferation of a cell expressing CD40.
15. (Amended) The human [anti-CD40] antibody of claim 14, wherein the cell is a B-cell.
16. (Amended) The human [anti-CD40] antibody of claim 12, wherein the antibody decreases expression of a protein.
17. (Amended) The human [anti-CD40] antibody of claim 16, wherein the protein comprises CD95, CD80 or CD86.
18. (Amended) The human [anti-CD40] antibody of claim 1, wherein the antibody increases a CD40 activity.
19. (Amended) The human [anti-CD40] antibody of claim 18, wherein the antibody increases proliferation of a cell expressing CD40.
20. (Amended) The human [anti-CD40] antibody of claim 19, wherein the cell is a B-cell.
21. (Amended) The human [anti-CD40] antibody of claim 18, wherein the antibody increases expression of a protein.
22. (Amended) The human [anti-CD40] antibody of claim 21, wherein the protein comprises CD95, CD80 or CD86.
23. (Amended) The human [anti-CD40] antibody of claim 1, further comprising a pharmaceutical formulation.

Please add the following new claims:

- Sub B3
AIA 3
62. (New) The human antibody or fragment of claim 1, wherein the antibody inhibits CD95 expression of Ramos B cells mediated by CD40 ligand in vitro, in the condition of 1 µg/ml of soluble CD40 ligand and 1 µg/ml of the antibody.
 63. (New) The human antibody or fragment of claim 1, wherein the antibody inhibits human B-cell proliferation mediated by CD40 ligand in vitro, in the condition of 1 µg/ml of soluble CD40 ligand and 10 nanogram/ml of the antibody.
 64. (New) The human antibody or fragment of claim 62 or 63, wherein the antibody has a Kd value of 0.8 to 4 nM, as determined by BiaCore® analysis.

